MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer

Cancer Cell

Volumn 25, Issue 4, 2014, Pages 469-483

  Valeri, Nicola ^a,j   Braconi, Chiara ^a,j   Gasparini, Pierluigi ^b   Murgia, Claudio ^c   Lampis, Andrea ^a,j   Paulus Hock, Viola ^a   Hart, Jonathan R ^d   Ueno, Lynn ^d   Grivennikov, Sergei I ^e   Lovat, Francesca ^b   Paone, Alessio ^b   Cascione, Luciano ^b,k   Sumani, Khlea M ^b   Veronese, Angelo ^f   Fabbri, Muller ^b,l,m   Carasi, Stefania ^b   Alder, Hansjuerg ^b   Lanza, Giovanni ^g   Gafa', Roberta ^g   Moyer, Mary P ^h   Ridgway, Rachel A ^c   Cordero, Julia ^c   Nuovo, Gerard J ^b   Frankel, Wendy L ^b   Rugge, Massimo ⁱ   Fassan, Matteo ⁱ   Groden, Joanna ^b   Vogt, Peter K ^d   Karin, Michael ^e   Sansom, Owen J ^c   Croce, Carlo M ^b   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b OHIO STATE UNIVERSITY   (United States)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e San Diego   (United States)

^f UNIVERSITY OF CHIETI   (Italy)

^g UNIVERSITY OF FERRARA   (Italy)

^h INCELL Corporation ^*  (United States)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^m CHILDREN S HOSPITAL LOS ANGELES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 135B; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; COLON POLYPOSIS; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATORY BOWEL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR INVASION; UPREGULATION;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, NUDE; MICRORNAS; TRANSFECTION;

EID: 84898430214     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.03.006     Document Type: Article

References (51)

1. Aust D.E., Terdiman J.P., Willenbucher R.F., Chang C.G., Molinaro-Clark A., Baretton G.B., Loehrs U., Waldman F.M. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer 2002, 94:1421-1427.
2. Biswas S., Chytil A., Washington K., Romero-Gallo J., Gorska A.E., Wirth P.S., Gautam S., Moses H.L., Grady W.M. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res. 2004, 64:4687-4692.
3. Borinstein S.C., Conerly M., Dzieciatkowski S., Biswas S., Washington M.K., Trobridge P., Henikoff S., Grady W.M. Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. Mol. Carcinog. 2010, 49:94-103.
4. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Network.
5. Catenacci D.V., Kozloff M., Kindler H.L., Polite B. Personalized colon cancer care in 2010. Semin. Oncol. 2011, 38:284-308.
6. Chen J., Huang X.F. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol. Ther. 2009, 8:1313-1317.
7. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
8. da Costa L.T., He T.C., Yu J., Sparks A.B., Morin P.J., Polyak K., Laken S., Vogelstein B., Kinzler K.W. CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling. Oncogene 1999, 18:5010-5014.
9. De Roock W., De Vriendt V., Normanno N., Ciardiello F., Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011, 12:594-603.
10. Dehm S., Senger M.A., Bonham K. SRC transcriptional activation in a subset of human colon cancer cell lines. FEBS Lett. 2001, 487:367-371.
11. Frattini M., Signoroni S., Pilotti S., Bertario L., Benvenuti S., Zanon C., Bardelli A., Pierotti M.A. Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res. 2005, 65:11227.
12. Gaedcke J., Grade M., Camps J., Søkilde R., Kaczkowski B., Schetter A.J., Difilippantonio M.J., Harris C.C., Ghadimi B.M., Møller S., et al. Therectal cancer microRNAome-microRNA expression in rectal cancer and matched normal mucosa. Clin. Cancer Res. 2012, 18:4919-4930.
13. Ghafouri-Fard S., Ousati Ashtiani Z., Sabah Golian B., Hasheminasab S.M., Modarressi M.H. Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer. Arch. Med. Res. 2010, 41:195-200.
14. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
15. Groden J., Joslyn G., Samowitz W., Jones D., Bhattacharyya N., Spirio L., Thliveris A., Robertson M., Egan S., Meuth M., et al. Response of colon cancer cell lines to the introduction of APC, a colon-specific tumor suppressor gene. Cancer Res. 1995, 55:1531-1539.
16. Guda K., Giardina C., Nambiar P., Cui H., Rosenberg D.W. Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors. Mol. Carcinog. 2001, 31:204-213.
17. Han M., Toli J., Abdellatif M. MicroRNAs in the cardiovascular system. Curr. Opin. Cardiol. 2011, 26:181-189.
18. Hart J.R., Liao L., Ueno L., Yates J.R., Vogt P.K. Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K). Cell Cycle 2011, 10:971-976.
19. Hinoi T., Akyol A., Theisen B.K., Ferguson D.O., Greenson J.K., Williams B.O., Cho K.R., Fearon E.R. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res. 2007, 67:9721-9730.
20. Hoogeboom D., Essers M.A., Polderman P.E., Voets E., Smits L.M., Burgering B.M. Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity. J.Biol. Chem. 2008, 283:9224-9230.
21. Ilyas M., Tomlinson I.P., Rowan A., Pignatelli M., Bodmer W.F. Beta-catenin mutations in cell lines established from human colorectal cancers. Proc. Natl. Acad. Sci. USA 1997, 94:10330-10334.
22. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11:849-864.
23. Lee G., Goretsky T., Managlia E., Dirisina R., Singh A.P., Brown J.B., May R., Yang G.Y., Ragheb J.W., Evers B.M., et al. Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 2010, 139:869-881. e1-e9.
24. Leedham S.J., Graham T.A., Oukrif D., McDonald S.A., Rodriguez-Justo M., Harrison R.F., Shepherd N.A., Novelli M.R., Jankowski J.A., Wright N.A. Clonality, founder mutations, and field cancerization inhuman ulcerative colitis-associated neoplasia. Gastroenterology 2009, 136:542-550. e6.
25. Lewis B.P., Shih I.H., Jones-Rhoades M.W., Bartel D.P., Burge C.B. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798.
26. Mahon P.C., Hirota K., Semenza G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15:2675-2686.
27. Marsh V., Winton D.J., Williams G.T., Dubois N., Trumpp A., Sansom O.J., Clarke A.R. Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nat. Genet. 2008, 40:1436-1444.
28. Matsuyama H., Suzuki H.I., Nishimori H., Noguchi M., Yao T., Komatsu N., Mano H., Sugimoto K., Miyazono K. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood 2011, 118:6881-6892.
29. Morin P.J., Vogelstein B., Kinzler K.W. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA 1996, 93:7950-7954.
30. Moyer M.P., Stauffer J.S., Manzano L.A., Tanzer L.R., Merriman R.L. NCM460, a normal human colon mucosal epithelial cell line. InVitro Cell Dev. Biol. Anim. 1996, 32:315-317.
31. Mukherji S., Ebert M.S., Zheng G.X., Tsang J.S., Sharp P.A., van Oudenaarden A. MicroRNAs can generate thresholds in target gene expression. Nat. Genet. 2011, 43:854-859.
32. Nagel R., le Sage C., Diosdado B., van der Waal M., Oude Vrielink J.A., Bolijn A., Meijer G.A., Agami R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008, 68:5795-5802.
33. Necela B.M., Carr J.M., Asmann Y.W., Thompson E.A. Differential expression of microRNAs in tumors from chronically inflamed or genetic (APC(Min/+)) models of colon cancer. PLoS ONE 2011, 6:e18501.
34. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
35. Qian J., Sarnaik A.A., Bonney T.M., Keirsey J., Combs K.A., Steigerwald K., Acharya S., Behbehani G.K., Barton M.C., Lowy A.M., Groden J. The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus. Gastroenterology 2008, 135:152-162.
36. Rehmsmeier M., Steffen P., Hochsmann M., Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004, 10:1507-1517.
37. Rojas A., Padidam M., Cress D., Grady W.M. TGF-beta receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-beta. Biochim. Biophys. Acta 2009, 1793:1165-1173.
38. Samuels Y., Diaz L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., Rago C., Huso D.L., Lengauer C., Kinzler K.W., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7:561-573.
39. Sansom O.J., Reed K.R., Hayes A.J., Ireland H., Brinkmann H., Newton I.P., Batlle E., Simon-Assmann P., Clevers H., Nathke I.S., et al. Loss of Apc invivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev. 2004, 18:1385-1390.
40. Sansom O.J., Reed K.R., van de Wetering M., Muncan V., Winton D.J., Clevers H., Clarke A.R. Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine. J.Biol. Chem. 2005, 280:28463-28467.
41. Sansom O.J., Meniel V.S., Muncan V., Phesse T.J., Wilkins J.A., Reed K.R., Vass J.K., Athineos D., Clevers H., Clarke A.R. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446:676-679.
42. Serrels A., Macpherson I.R., Evans T.R., Lee F.Y., Clark E.A., Sansom O.J., Ashton G.H., Frame M.C., Brunton V.G. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol. Cancer Ther. 2006, 5:3014-3022.
43. Shaulian E. AP-1-The Jun proteins: Oncogenes or tumor suppressors in disguise?. Cell. Signal. 2010, 22:894-899.
44. Sjöblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
45. Valeri N., Croce C.M., Fabbri M. Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genomics Proteomics 2009, 6:195-204.
46. Valeri N., Gasparini P., Fabbri M., Braconi C., Veronese A., Lovat F., Adair B., Vannini I., Fanini F., Bottoni A., et al. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl. Acad. Sci. USA 2010, 107:6982-6987.
47. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008, 14:6735-6741.
48. Xu X.L., Yu J., Zhang H.Y., Sun M.H., Gu J., Du X., Shi D.R., Wang P., Yang Z.H., Zhu J.D. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J. Gastroenterol. 2004, 10:3441-3454.
49. Yeatman T.J. A renaissance for SRC. Nat. Rev. Cancer 2004, 4:470-480.
50. Yoon J., Koo K.H., Choi K.Y. MEK1/2 inhibitors AS703026 andAZD6244 may be potential therapies for KRAS mutated colorectal cancerthat is resistant to EGFR monoclonal antibody therapy. Cancer Res. 2011, 71:445-453.
51. Yuki D., Lin Y.M., Fujii Y., Nakamura Y., Furukawa Y. Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers. Oncol. Rep. 2004, 12:275-280.